Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361

Journal of the National Cancer Institute

Volumn 96, Issue 1, 2004, Pages 56-67

  Calabrese, Christopher R ^a   Almassy, Robert ^b   Barton, Stephanie ^a   Batey, Michael A ^a   Calvert, A Hilary ^a   Canan Koch, Stacie ^b   Durkacz, Barbara W ^a   Hostomsky, Zdenek ^b   Kumpf, Robert A ^b   Kyle, Suzanne ^a   Li, Jianke ^b   Maegley, Karen ^b   Newell, David R ^a   Notarianni, Elena ^a   Stratford, Ian J ^c   Skalitzky, Donald ^b   Thomas, Huw D ^a   Wang, Lan Zhen ^a   Webber, Stephen E ^b   William, Kaye J ^c   Curtin, Nicola J ^a   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AG 14361; ALKYLATING AGENT; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; DNA; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PD 128763; PENTOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ASSAY; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA ALKYLATION; DNA MICROARRAY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIZATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; GAMMA RADIATION; GENE EXPRESSION; HOMOGENATE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LETHALITY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; STATISTICAL ANALYSIS; TOXICITY TESTING; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; X RAY;

EID: 10744226451     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh005     Document Type: Article

References (59)

1. Smith S. The world according to PARP. Trends Biochem Sci 2001;26: 174-9.
2. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor [published erratum appears in Trends Biochem Sci 1994;19:250]. Trends Biochem Sci 1994;19:172-6.
3. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000;39: 7559-69.
4. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45: 73-85.
5. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995;77:408-22.
6. Barret JM, Hill BT. DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs 1998;9:105-23.
7. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992;356:356-8.
8. Curtin NJ, Golding BT, Griffin RJ, Newell DR, Roberts MJ, Srinivasan S, et al. New PARP inhibitors for chemo- and radio-therapy of cancer. In: deMurcia G, Shall S, editors. From DNA damage and stress signalling to cell death: poly ADP-ribosylation reactions. Oxford (U.K.): Oxford University Press; 2000. p. 177-206.
9. Molinete M, Vermeulen W, Burkle A, Menissier-de Murcia J, Kupper JH, Hoeijmakers JH, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 1993;12:2109-17.
10. Ding R, Smulson M. Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influences on genomic stability, chromatin organization, and carcinogen cytotoxicity. Cancer Res 1994; 54:4627-34.
11. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7.
12. Purnell MR, Whish WJ. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 1980;185:775-7.
13. Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM, Sebolt-Leopold JS. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des 1991;6: 107-17.
14. Banasik M, Komura H, Shimoyama M, Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 1992;267:1569-75.
15. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998;78:1269-77.
16. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001;84:106-12.
17. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6: 2860-7.
18. Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, et al. Combined treatment with temozolomide and poly(ADP-ribose) polyrnerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002;99:2241-4.
19. Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem 2002;45:4961-74.
20. Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 2003;46:210-3.
21. Robertson EJ. Embryo-derived stem cell lines. In: Robertson EJ, editor. Teratocarcinomas and embryonic stem cells: a practical approach. Oxford (U.K.): IRL Press, Ltd.; 1987. p. 71-112.
22. Chen TR. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977;104:255-62.
23. Jung S, Miranda EA, de Murcia JM, Niedergang C, Delarue M, Schulz GE, et al. Crystallization and X-ray crystallographic analysis of recombinant chicken poly(ADP-ribose) polymerase catalytic domain produced in Sf9 insect cells. J Mol Biol 1994;244:114-6.
24. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54(Pt 5):905-21.
25. Mohamadi F, Richards NG, Guida WC, Liskamp R, Lipton M, Caufield C, et al. Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comp Chem 1990; 11: 440-67.
26. Marsischky GT, Wilson BA, Collier RJ. Role of glutamic acid 988 of human poly-ADP-ribose polymerase in polymer formation. Evidence for active site similarities to the ADP-ribosylating toxins. J Biol Chem 1995; 270:3247-54.
27. Grube K, Küpper JH, Bürkle A. Direct stimulation of poly(ADP-ribose) polymerase in permeabilised cells by double-stranded DNA oligomers [published erratum appears in Anal Biochem 1991;195:378]. Anal Biochem 1991;193:236-9.
28. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
29. Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997; 15:1359-67.
30. Sandberg R, Yasuda R, Pankratz DG, Carter TA, Del Rio JA, Wodicka L, et al. Regional and strain-specific gene expression mapping in the adult mouse brain. Proc Natl Acad Sci U S A 2000;97:11038-43.
31. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14:1675-80.
32. Potter GW. Analysis of biological molecules: an introduction to principles instrumentation and techniques. 1st ed. London (U.K.): Chapman and Hall; 1995. p. 202.
33. Thomas CD, Stem S, Chaplin DJ, Guichard M. Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Radiother Oncol 1996;39:235-41.
34. Mendoza-Alvarez H, Alvarez-Gonzalez R. Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J Biol Chem 1993;268:22575-80.
35. Leopold W, Sebolt-Leopold JS. Chemical approaches to improve radiotherapy. In: Valeriote FA, Corbett TH, Baker LH, editors. Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Boston (MA): Kluwer Academic Publishers; 1992. p. 179-96.
36. Weichselbaum RR, Little JB. The differential response of human tumours to fractionated radiation may be due to a post-irradiation repair process. Br J Cancer 1982;46:532-7.
37. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
38. Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995;34:571-87.
39. Berthet N, Boturyn D, Constant JF. DNA repair inhibitors. Expert opinion on therapeutic patents. 1999;9:401-15.
40. Martin DS, Stolfi RL, Nord LD, Colofiore JR. Enhancement of chemotherapeutically-induced apoptosis in vivo by biochemical modulation of poly(ADP-ribose) polymerase. Oncol Rep 1996;3:317-22.
41. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
42. Barendsen GW, Van Bree C, Franken NA. Importance of cell proliferative state and potentially lethal damage repair on radiation effectiveness: implications for combined tumor treatments (review). Int J Oncol 2001;19: 247-56.
43. Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP. Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 2002;100:615-7.
44. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
45. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MS, Cole S, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000;82:1984-90.
46. el-Said A, Menke D, Dorie MJ, Brown JM. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. Radiat Oncol Investig 1999;7:163-9.
47. Lammering G, Hewit TH, Hawkins WT, Contessa JN, Reardon DB, Lin PS, et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 2001;93:921-9.
48. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002;86:1157-61.
49. Arris CE. The evaluation of novel inactivators of O6-methyl-guanine-DNA methyltransferase. [PhD thesis]. Newcastle upon Tyne (U.K.): Univ. of Newcastle upon Tyne; 1998.
50. Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M. N-(2-chloroethyl)-N′-cyclohexyl-N′-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res 1998;58:135-41.
51. Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 2002;40:354-67.
52. Margison GP, Santibanez Koref MF, Povey AC. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002;17: 483-7.
53. Wedge SR, Porteous JK, Newlands ES. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996;74:1030-6.
54. Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, Gerson SL. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Murat Res 2001; 485:269-81.
55. Lunn JM, Harris AL. Cytotoxicity of 5-(3-methyl-1-triazino)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide. Br J Cancer 1988;57:54-8.
56. Kamm YJ, Heerschap A, Wagener DJ. Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma. Eur J Cancer 2000;36:1180-6.
57. Hirst DG, Kennovin GD, Flitney FW. The radiosensitizer nicotinamide inhibits arterial vasoconstriction. Br J Radiol 1994;67:795-9.
58. Burns DM, Ruddock MW, Walker MD, Allen JM, Kennovin GD, Hirst DG. Nicotinamide-induced vasoconstriction: lack of dependence on agonist signalling pathways. Eur J Pharmacol 1999;374:213-20.
59. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37.